Details for: SMOFKABIVEN
Company: FRESENIUS KABI CANADA LTD
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02440695 | SMOFKABIVEN | SOYBEAN OIL; MEDIUM CHAIN TRIGLYCERIDES (MCT); OLIVE OIL; FISH OIL; DEXTROSE; LYSINE (LYSINE ACETATE); PHENYLALANINE; LEUCINE; VALINE; THREONINE; METHIONINE; ISOLEUCINE; TRYPTOPHAN; ALANINE; ARGININE; GLYCINE; PROLINE; HISTIDINE; SERINE; TAURINE; TYROSINE; SODIUM ACETATE TRIHYDRATE; POTASSIUM CHLORIDE; SODIUM GLYCEROPHOSPHATE; MAGNESIUM SULFATE; CALCIUM CHLORIDE; ZINC SULFATE HEPTAHYDRATE | 1.14 G / 100 ML; 1.14 G / 100 ML; 0.95 G / 100 ML; 0.57 G / 100 ML; 12.7 G / 100 ML; 0.34 G / 100 ML; 0.26 G / 100 ML; 0.38 G / 100 ML; 0.31 G / 100 ML; 0.22 G / 100 ML; 0.22 G / 100 ML; 0.25 G / 100 ML; 0.1 G / 100 ML; 0.71 G / 100 ML; 0.61 G / 100 ML; 0.56 G / 100 ML; 0.57 G / 100 ML; 0.15 G / 100 ML; 0.33 G / 100 ML; 0.05 G / 100 ML; 0.02 G / 100 ML; 0.17 G / 100 ML; 0.23 G / 100 ML; 0.21 G / 100 ML; 0.061 G / 100 ML; 0.028 G / 100 ML; 0.00066 G / 100 ML | EMULSION | INTRAVENOUS |
Summary Reports
Regulatory Decision Summary
Summary Safety Review - Amino-acid solutions for parenteral nutrition - Assessing the potential risk of death in premature infants when the solutions are not protected from light
Summary Safety Review - Amino-acid solutions for parenteral nutrition - Assessing the potential risk of death in premature infants when the solutions are not protected from light
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.